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Abstract
Background: In many preclinical AIDS research studies, antiretroviral therapy (ART) is administered to
experimentally simian immunodeficiency (SIV)-infected rhesus macaques for reduction of viral load to undetectable
levels. Prolonged treatment of macaques with a high dose of PMPA (9-[2-(r)-(phosphonomethoxy) propyl] adenine
or tenofovir; 30 mg/kg of body weight subcutaneously once daily) can result in proximal renal tubular dysfunction,
a Fanconi-like syndrome characterized by glucosuria, aminoaciduria, hypophosphatemia, and bone pathology. In
contrast, chronic administration of a low dose of PMPA (10 mg/kg subcutaneously once daily) starting at birth
does not seem to be associated with any adverse health effects within 3 years of treatment. In contrast to PMPA,
limited information on systemic toxicity in rhesus monkeys is available for FTC (5-fluoro-1-(2R,5S)-[2-
(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; emtricitabine) and stavudine (d4T).
Results: In this study, the clinical and biochemical correlates of tubular nephrosis in SIV-infected rhesus macaques
associated with systemic administration of high-dose ART consisting of the three nucleoside analog inhibitors
PMPA, FTC, and d4T were investigated. It was found that acute renal failure was uncommon (7.1% of treated
animals) and that morphologic evidence of nephropathy, which persisted for more than 300 days following
discontinuation of the drug cocktail, was more frequent (52.4% of treated animals). While parameters from single
time points lacked predictive value, biochemical alterations in Blood Urea Nitrogen (BUN) and phosphorus were
frequently identified longitudinally in the blood of ART-treated animals that developed evidence of nephropathy,
and these longitudinal changes correlated with disease severity.
Conclusions: Recommendations are proposed to limit the impact of drug-induced renal disease in future SIV
macaque studies.
Background
The nucleotide reverse transcriptase inhibitor (NRTI)
PMPA or tenofovir has become one of the most com-
monly used antiretroviral drugs due to its favorable effi-
cacy and safety profile, based on data collected over
more than 9 years for HIV-infected adults. The acyclic
nucleoside phosphonate PMPA is renally excreted by a
combination of glomerular filtration and active tubular
secretion [1]. The effective uptake of acyclic nucleoside
phosphonates by organic anion transporters in proximal
tubules leads to accumulation in tubular cells and dose-
limiting toxicity in animals [2]. Renal toxicity is usually
manifested as renal insufficiency and proximal renal
tubular dysfunction (PRTD). FTC or emtricitabine is the
(-) enantiomer of a thio analog of cytidine, which differs
from other cytidine analogs in that it has a fluorine in
the 5-position. It is another nucleoside analog HIV-1
reverse transcriptase inhibitor and also mainly elimi-
nated by the kidney. ZERIT
® is the brand name for d4T
or stavudine, a synthetic thymidine nucleoside analogue.
D4T is phosphorylated by cellular kinases to the active
metabolite d4T triphosphate, which inhibits the activity
of HIV-1 reverse transcriptase (RT) by competing with
the natural substrate thymidine triphosphate and by
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tion into viral DNA. D4T triphosphate inhibits cellular
DNA polymerases b and g and markedly reduces the
synthesis of mitochondrial DNA. Urinary excretion is
the major route of d4T elimination.
Although systemic ART is clearly of benefit, a variety
of antiretroviral drugs including protease inhibitors and
NRTIs, have been linked to nephrotoxicity [3]. SIV-
infected macaques also develop renal disease that
mimics the scope and etiology of that observed in HIV-
infected people. Rhesus macaques develop opportunistic
infections such as SV40, cytomegalovirus and adenovirus
infection that may produce renal pathology and resem-
ble the disease processes recognized in HIV-infected
patients. Furthermore, a segmental glomerulosclerosis
has been described in SIV-infected animals that have
progressed to AIDS, which is similar morphologically to
the HIV-nephropathy observed in human patients [4-6].
Finally macaques may also develop renal dysfunction
subsequent to antiretroviral therapy with PMPA [7-11].
PMPA is the biologically active metabolite of the pre-
scription drug Viread
®.I ti sc o m m o n l yu s e di nS I V
pathogenesis studies because it can be administered by
the parenteral route and is highly effective at reducing
viral loads. Previous work of others has revealed that
long-term administration of PMPA at 30 mg/kg resulted
in a Fanconi-like syndrome with glucosuria, aminoaci-
duria, hypophosphatemia, growth restriction and bone
pathology [2]. In this report, the serum biochemical cor-
relates of renal morphologic alterations in SIV-infected
macaques that received PMPA, d4T and FTC combina-
tion therapy are described and guidelines to prevent and
identify serious renal sequellae in future experiments are
proposed.
Results
Effectiveness of ART in reducing SIV RNA load
As described in zur Megede et al. [12], ART (PMPA,
FTC, and d4T) was administered during the chronic
phase of SIV infection (13 weeks post infection (wpi))
and was continued until 41 wpi. Viral load was very effi-
ciently controlled by ART, dropping below the assay
detection limit (<200 RNA copies/ml) in most of the
animals by 20 wpi, and only rebounded upon disconti-
nuation of ART.
Acute renal failure may be associated
with NRTI-based ART
Thirty-three rhesus macaques (Macaca mulatta)w e r e
initially enrolled in the study [12]. Treatment groups
and disease outcomes are provided in Table 1. Of these
animals, 30 were inoculated with SIVmac239 and 28
received antiretroviral treatments consisting of PMPA,
FTC, and d4T, which was highly effective in controlling
viral replication in the majority of cases. Two animals
were rapid progressors and had to be euthanized due to
the development of AIDS-like symptoms at 8 and 13
wpi, respectively (3445, 3529). Another two animals
were euthanized 4 and 5 weeks after start of ART treat-
ment, respectively, due to opportunistic infections (3406,
3448), and one animal died from cardiac arrest during
anesthesia (3528). At week 22, another six animals were
excluded from the study due to incomplete virus control
under ART (3443, 3517, 3519, 3520, 3521, 3523). The
remaining 19 animals, including nine MamuA01+ ani-
mals, were randomly distributed into three groups
according to their MamuA01 status and viral load.
Seven animals received ART only (3447, 3451, 3452,
3453, 3511, 3515, 3684), in six animals immunization
with SIV DNA by IM electroporation was conducted
four times in four-week intervals (3444, 3522, 3524,
3526, 3527, 3530), and six animals additionally received
50,000 IU/kg IL-2 administered twice daily by the sub-
cutaneous route from day 2-16 following immunization
(3449, 3512, 3514, 3516, 3518, 3525). Of the 28 animals
that received PMPA, two (3406 and 3448) had biochem-
ical evidence of acute renal failure that developed 26
and 31 days, respectively, following initiation of ART.
Abnormalities included marked and abrupt increases in
serum BUN, creatinine and calcium (Table 1). Four ani-
mals were euthanized because of continuing high virus
replication or onset of SIV-related disease and, although
tissues were not evaluated, they did not have biochem-
ical evidence of renal failure. One animal died peracu-
tely, and autolysis prevented interpretation of tissue
samples. The remaining 21 animals were followed by
sequential evaluation of serum chemistries, and renal
tissue was evaluated morphologically upon euthanasia.
None of these animals developed biochemical evidence
of acute or chronic renal failure. Histologically, acute
renal failure was documented in 7.1% (2/28) of the ani-
mals receiving ART, for which suitable samples were
available for analysis. Both cases occurred during the
administration of high-dose PMPA (30 mg/kg) in com-
bination with FTC and d4T and resulted in rapidly pro-
gressive and nonreversible acute renal failure.
Morphologic evidence of ART nephropathy is common
and persistent
Twenty-one cases were submitted for necropsy evalua-
tion and were suitable for microscopic evaluation of
renal morphology. The range of survival following com-
pletion of ART for these animals was from 122 to 300
days. Three NHP were euthanized for health-related rea-
sons prior to study end, and 18 animals were euthanized
at the end of the study. 52.4% (11/21) of these animals
developed morphologic evidence of ART nephropathy.
A variety of changes were observed in effected animals
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Page 2 of 11Table 1 Summary of animal groups and disease outcomes
Animal
ID
Age
(yrs)*
Weight
(kg)*
MHC type Reason for death Survival
(months)
SIV ART
Treatment
ART
nephropathy
Renal failure
3406 14.0 13.5 A02 nephropathy 4 yes ART likely BUN 181, Ca/P 15.6/9.6,
creatinine 23.3
3442 5.0 8.7 B01 open 11 no - n/a n/a
3443 5.9 8.3 - autolysis 14 yes ART unknown unknown
3444 5.5 10.9 A01, B01 study ended/
euthanized
18 yes ART+DNA yes no biochemical evidence
3445 5.2 7.5 A08 open 2 yes - n/a n/a
3446 7.3 9.3 A08 n/a n/a no - n/a n/a
3447 6.3 11.5 A01, A08 study ended/
euthanized
18 yes ART yes no biochemical evidence
3448 5.4 5.7 - nephropathy 4 yes ART likely BUN 113, Ca/P12.9/4.8,
creatinine 6.4
3449 6.6 13.8 A08 study ended/
euthanized
18 yes ART+DNA
+IL-2
yes no biochemical evidence
3451 8.6 10.0 - study ended/
euthanized
18 yes ART yes no biochemical evidence
3452 7.5 9.3 A08 study ended/
euthanized
18 yes ART yes no biochemical evidence
3453 6.8 8.8 - study ended/
euthanized
18 yes ART no no biochemical evidence
3511 5.4 9.2 A01 study ended/
euthanized
20 yes ART no no biochemical evidence
3512 5.3 6.7 A02 granulomatous
hepatitis
17 yes ART+DNA
+IL-2
no no biochemical evidence
3514 5.3 9.0 A01, A08,
B01
study ended/
euthanized
19 yes ART+DNA
+IL-2
yes no biochemical evidence
3515 5.4 10.2 A01 study ended/
euthanized
19 yes ART yes no biochemical evidence
3516 5.4 10.1 A01, A08 study ended/
euthanized
19 yes ART+DNA
+IL-2
yes no biochemical evidence
3517 4.7 5.2 - poor viral control 10 yes ART unknown no biochemical evidence
3518 5.4 8.9 - study ended/
euthanized
19 yes ART+DNA
+IL-2
yes no biochemical evidence
3519 5.4 7.4 A02, A08,
B01
study ended/
euthanized
18 yes ART no no biochemical evidence
3520 4.6 4.4 A08, B01 poor viral control 10 yes ART unknown no biochemical evidence
3521 4.7 5.9 A01, B01 poor viral control 10 yes ART unknown no biochemical evidence
3522 5.5 7.2 A01 study ended/
euthanized
20 yes ART+DNA no no biochemical evidence
3523 5.2 6.9 A08 SIVE/Pneumonia 17 yes ART no no biochemical evidence
3524 5.5 9.2 A01 study ended/
euthanized
19 yes ART+DNA yes no biochemical evidence
3525 5.4 8.3 A01, B01 study ended/
euthanized
19 yes ART+DNA
+IL-2
no no biochemical evidence
3526 5.7 6.5 A08, B01 study ended/
euthanized
20 yes ART+DNA no no biochemical evidence
3527 5.7 10.7 A08 study ended/
euthanized
20 yes ART+DNA no no biochemical evidence
3528 4.6 5.5 A01, B01 diseased 5 yes ART unknown no biochemical evidence
3529 4.4 5.1 A08 open 3 yes - n/a n/a
3530 5.3 10.7 A02, B01 study ended/
euthanized
19 yes ART+DNA yes no biochemical evidence
3680 8.8 14.4 B01 n/a n/a no - n/a n/a
3684 6.2 10.9 B01 pneumonia 14 yes ART yes no biochemical evidence
*at study end
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Page 3 of 11(Figure 1): 1) nuclear dysplasia of proximal convoluted
tubular (PCT) epithelium (anisonucleosis, meganucleo-
sis, nuclear lobulation, heterochromaisa and/or cytoplas-
mic invaginations) (100.0%); 2) interstitial fibrosis
(91.6%); 4) PCT basophilia (75.0%); 5) tubular proteino-
sis (75.0%); 6) ongoing tubular necrosis (75.0%); 7) cyto-
megaly of PCT (66.7%); 8) interstitial nephritis (50.0%);
and 9) cellular casts (8.3%).
Since all NHP were male, there was no correlation
with sex (Table 1). The NHP that were diagnosed with
nephropathy (n = 12; mean age 6.1 years) were slightly
older than the animals without nephropathy (n = 9;
mean age 5.6 years), but the difference was not statisti-
cally significant (p = 0.22; two tailed t-test). In contrast,
the NHP that were diagnosed with nephropathy (n = 12;
mean body weight 10.4 kg) were slightly heavier than
the animals without nephropathy (n = 9; mean body
weight 8.0 kg), and the difference was statistically signif-
icant (p = 0.0008; two tailed t-test). No obvious correla-
tion between development of nephropathy and the
MHC types MamuA01, A02, A08, and B01 could be
detected (Table 1). No differences were observed in
those animals receiving IL - 2a sac o m p o n e n to ft h e i r
vaccine regimen (Table 1). These findings are consistent
with alterations previously described in both humans
and macaques with ART nephropathy. Nuclear changes
observed in the PCTs were unique and have not been
observed outside the context of ART nephropathy in
SIV-infected macaques. While morphologic evidence of
ART nephropathy was frequent, clinical disease evi-
denced by overt azotemia or renal failure was not
observed in animals following discontinuation of drug.
Biochemical differences in serum are observed frequently
at different stages of treatment and disease
Longitudinal changes in serum chemistry were exam-
ined at different stages of disease and treatment and
revealed an initial increase in BUN and creatinine and
decrease in phosphorus, which coincided with ART
initiation (Figure 2). These values tended to normalize
following PMPA dose reduction from 30 to 20 mg/kg.
Following discontinuation of ART, phosphorus
A B  C 
D E  F 
G
Figure 1 Morphologic features of ART nephropathy. Ectasia of renal tubules containing eosinophilic proteinaceous material (tubular
proteinosis) (A) and focal lymphocytic infiltrate (B). Mild cytomegaly and anisonucleosis of proximal convoluted tubule (PCT) (C). Marked nuclear
dysplasia with mild cytomegaly and tubular ectasia (D). Focal necrosis of PCT epithelial cell (E). Nuclear dysplasia with cytoplasmic inclusion and
nuclear vesiculation (F) and early lobulation (G).
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Page 4 of 11increased further, and there were upward trends in both
creatinine and BUN. One-way analysis of variance
(Anova) was used to compare values at base line, initia-
tion of ART, 2 weeks of ART, 4 weeks of ART, termina-
tion of ART, and end of study (Table 2 and Figure 3).
Differences were observed for calcium (p < 0.001), phos-
phorus (p = 0.0042), alkaline phosphatase (p < 0.0001),
Ca/P (p < 0.001), creatinine/phosphorus (p < 0.0001),
and BUN/phosphorus (p < 0.001). A post (ANOVA) test
pairwise comparison was performed to examine differ-
ences at select time points with the result that
statistically significant increases in the calcium/phos-
phorus ratio (p < 0.001), the creatinine/phosphorus ratio
(p < 0.001), and alkaline phosphatase (p < 0.05), and a
statistically significant decrease in phosphorus (p < 0.05)
were present after 4 weeks of ART compared to values
obtained at the initiation of ART (Table 2). Further dif-
ferences were not observed at the termination of ART
suggesting that only the higher dose of PMPA was asso-
ciated with adverse outcomes or that compensatory
mechanisms had come into play for reducing serum
chemistry changes.
Individual serum chemistry values lack predictive
value of chronic disease
To determine whether serum chemistry values were pre-
dictive of the development of chronic ART nephropathy,
values were compared to individual and composite histo-
logic scores. No statistically significant correlations were
observed at base line, initiation of ART, 2 weeks ART, or
4 weeks ART for BUN, creatinine, phosphorus, calcium,
albumin, globulin, glucose or alkaline phosphatase. At dis-
continuation of ART a negative correlation was observed
between histologic score and phosphorus (r = -0.5360;
95% CI -0.7964 to -0.1079; p = 0.018) and positive correla-
tions were observed with Ca/P (r = 0.4826; 95% CI 0.324
to 0.7684; p = 0.0364) and Crea/P (r = 0.4631; 95% CI
0.1109 to 0.7579; p = 0.0459) (Figure 4). At study termina-
tion, a positive correlation was observed between creati-
nine and composite histologic score (r = 0.4947; 95% CI
0.0372 to 0.7817; p = 0.037). Examination of individual
histologic parameters revealed an unexpected relationship
between serum sodium levels at 2 wks of ART and
ongoing pathology in the proximal convoluted tubules at
death (slope = 2.308; p = 0.0009) (Figure 5). This suggests
that factors influencing hydration during treatment regi-
men may impact disease course.
While differences were observed within groups as a
whole, values obtained from individual animals during
ART were of limited use in predicting those animals
that would develop morphologic alterations of disease.
Since only two animals developed acute renal failure, it
is difficult to determine the predictive value of serum
chemistry parameters for severe disease. Alterations in
BUN and creatinine were only observed within 4 days of
death suggesting that they lack sensitivity and do not
represent useful predictive markers. A mild hypopho-
sphatemia was observed in one animal approximately
two weeks prior to death, but was not observed in the
second animal.
Longitudinal changes in serum chemistry values
correlate with chronic disease
To determine whether longitudinal alterations in bio-
chemical values were associated with morphologic
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Figure 2 Longitudinal changes in serum BUN, creatinine and
phosphorus following SIV infection and ART treatment.
Longitudinal changes in Blood Urea Nitrogen, creatinine, and
phosphorus in the serum of ART-treated, SIV-infected rhesus
macaques. Shown are mean and standard deviation for a period of
79 weeks after SIV infection. Durations of PMPA treatment with the
30 mg/kg and 20 mg/kg dose are indicated.
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performed for serum chemistry values from individual
animals, and the slope of change was compared to com-
posite histologic scores. Positive correlations were
observed between composite histologic scores and
changes in BUN (r = 0.7234; 95% CI 0.4131 to 0.8832; p
= 0.0003) and phosphorus (r = 0.4631; 95% CI 0.02575
to 0.7516; p = 0.0398) (Figure 6). No statistically signifi-
cant correlation was observed between changes in
serum creatinine and composite histologic score. In all,
9 of 21 animals had statistically significant positive
slopes for BUN over time. For animals with no evidence
of ART nephropathy 11.1% (1/9) had a positive slope
compared to 66.7% (8/12) with evidence of ART
nephropathy (p = 0.0244; Fischer exact test). These find-
ings indicate that morphologic alterations resulted in
biochemical changes consistent with progressive renal
disease and suggest that over time some animals may
have progressed to renal failure.
Discussion and Conclusion
The results presented indicate that ART nephropathy
was common and persistent in SIV-infected rhesus
macaques receiving combination PMPA-containing
ART. Animals developed morphologic and biochemical
evidence of disease despite normal renal function at the
onset of the study. This is in contrast to human
patients, in whom disease is said to be infrequent and
associated with pre-existing renal pathology. These dif-
ferences may be related to differences in species, drug
or drug dose, and route. The dose of the prodrug
tenofovir disoproxyl fumarate (TDF; Viread
®) in human
patients is substantially lower on a per kilogram basis
than the equivalent PMPA dose used in rhesus maca-
ques, which in combination with species differences in
drug pharmacokinetics results in lower plasma drug
levels in humans [13,14]. In addition, while Viread
® is
given orally in human patients, PMPA is administered
as a single subcutaneous injection once daily in maca-
ques, which may further increase peak plasma drug
values. In addition, the FTC dose that was used in these
studies (50 mg/kg) is also higher than the equivalent
regimen in humans. Others demonstrated that a dose of
20 mg/kg of FTC is equivalent to the human dose [15].
This higher dose of FTC may also have contributed to
toxicity. However, for d4T, the dose administered for
NHP in this study (2.4 mg/kg/day) was slightly lower
than the dose recommended for humans, based on a
body surface conversion model [16]. Although morpho-
l o g i ce v i d e n c eo fA R Tn e p h r o p a t h yw a sf r e q u e n t ,a s s o -
ciated acute renal failure was less common (7.1%) and
overt chronic renal failure demonstrated by azotemia
following completion of the ART regimen was not
observed over the time period monitored. Changes in
BUN over time suggest that if a longer follow-up period
is allowed, a subset of animals might develop chronic
renal failure. In the present study, the occurrence of
ART nephropathy after termination of treatment did
not appear to effect clinical outcome or survival. None-
theless, subclinical renal dysfunction could impact
experimental outcome through alteration of the pharma-
cokinetics of co-administered drugs, changes in calcium/
Table 2 Comparison of Ca, P, Ca/P, BUN/P, Creatinine/P and alkaline phosphatase levels at select time points during
treatment and disease
Initiation ART
vs 2 wks ART
Initiation ART
vs 4 wks ART
Initiation ART
vs ART end
Initiation ART
vs study end
Ca Mean Diff. 0.1222 0.4667 0.5548 -0.4759
P value
P Mean Diff. -0.4593 -1.037 -0.5944 -0.9722
P value P < 0.05
Ca/P Mean Diff. 0.2767 0.9773 0.5025 0.4104
P value P < 0.001
BUN/P Mean Diff. -0.237 1.844 -0.3889 0.4556
P value
Crea/P Mean Diff. 0.07223 0.3088 0.1579 0.1963
P value P < 0.001
Alk Phos Mean Diff. -82.33 167.4 107.9 0.6296
P value P < 0.05
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Page 6 of 11phosphorus balance or initiation of other sequellae of
chronic renal disease. It was also found that animals
may have substantial morphologic alterations at the
light microscopic level and normal BUN and creatinine
levels in serum, reinforcing the relative insensitivity of
these tests in diagnosing renal pathology. For these rea-
sons, investigators should be made aware of ART
nephropathy, and a better understanding of risk factors
associated with its development should be sought.
The toxic effects of PMPA on bone and kidney in
SIV-infected macaques have previously been described
in detail [2,17]. These findings included growth restric-
tion and biochemical and morphologic features of renal
tubular dysfunction, which were frequently observed in
animals receiving PMPA at 30 mg/kg for periods
exceeding 8 months [2]. The results presented here dif-
fer in that short term (30 days) administration of PMPA
at this dose was associated with acute renal failure in a
small subset of animals and was more frequently asso-
ciated with morphologic and biochemical evidence of
renal dysfunction for up to 300 days following cessation
of treatment. The reason for this difference is unknown,
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Figure 3 Alterations in serum chemistry values at defined time points during the course of treatment and disease. Alterations in blood
urea nitrogen, creatinine, phosphorus, calcium, the Ca/P ratio and alkaline phosphatase were plotted at critical time points (1 = baseline, 2 =
initiation of ART, 3 = 2 weeks ART, 4 = 4 weeks ART, 5 = ART end, 6 = study end). Grey dots represent individual animals and black lines
represent the mean.
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Page 7 of 11and since our cohort received combination therapy, it is
possible that co-administration of the other NRTIs, d4T
and FTC, may have potentiated the nephrotoxic effects
of PMPA [18-21]. This cohort was also substantially
older than the neonatal and juvenile animals previously
examined. Van Rompay reported that PMPA renal clear-
ance was lower in adult as compared to juvenile ani-
m a l s ,a n dt h u sa g ed i f f e r e n c e sm a yp l a yar o l ei n
determining disease susceptibility and course [2]. Lower
PMPA clearance may allow for higher plasma concen-
trations to be achieved and promote drug accumulation
within the PCT epithelium, thereby exacerbating renal
toxicity. Once renal damage occurs, PMPA clearance
may decrease leading to a further reduction in tubular
function.
It was found that individual serum chemistry values
were of limited use in predicting acute renal or persis-
tent renal pathology. The identified changes were con-
sistent with the proposed pathogenesis of ART
nephropathy and changes previously observed in
humans and macaques.
Several recommendations are proposed to reduce the
impact of ART nephropathy on future studies:
1) Consider reduction of the 30 mg/kg PMPA dose or
shortening of therapy duration
Cases of acute renal failure were observed during or
shortly after completion of the 30 mg/kg dose regimen.
Furthermore, biochemical abnormalities observed after
the 4 weeks of ART had largely resolved at termination
of ART. While this may have been due to compensatory
changes, more likely it was the result of the dose
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Page 8 of 11reduction. If it is felt that an initial 30 mg/kg dose is
needed to achieve adequate virologic control, the dura-
tion of the higher dose could be reduced to 2 weeks.
This would likely decrease the incidence of acute renal
f a i l u r ea n dA R Tn e p h r o p a t h ya n dm a yb ep a r t i c u l a r l y
important in older animals or animals administered
other potentially nephrotoxic drugs.
2) Defined criteria should be established for
discontinuation of ART
Acute renal failure appeared to develop rapidly, and bio-
chemical changes in the serum did not appear until sig-
nificant renal dysfunction was apparent. Unfortunately,
serum chemistry values were of limited value in predict-
ing acute renal failure. Defined biochemical criteria to
remove animals from NRTI-based ART should include
BUN >30 mg/dl, creatinine >2.0 mg/dl and phosphorus
<3.0 mg/dl. Because of the rapidly progressive nature of
renal dysfunction in this condition, such criteria may
still be of limited use. If acute nephropathy is recog-
nized, concurrent administration of intravenous fluids
and judicious use of diuretics should be considered.
3) Management of subclinical dehydration
The positive correlation between serum sodium at 2
weeks on ART and the severity of nephropathy at the
termination of the study was striking. While individual
sodium levels lack predictive value, this finding suggests
that mild dehydration during the early phase of treat-
m e n tm a yp r e d i s p o s et om o r es e v e r er e n a lc h a n g e s .
Options to improve hydration during this critical period,
such as supplementing animals’ water consumption with
juice or fruit, should be considered and overt clinical
dehydration should be treated aggressively.
4) Consider increasing the frequency of serum chemistry
evaluation during high dose treatment
Increasing the frequency of serum chemistry evaluation
during high dose therapy may increase the ability to
detect changes associated with acute renal failure allow-
ing time to discontinue drug and intervene. Use of
weekly samples during this time should be considered.
Similarly, if there is a means to measure water con-
sumption or urine production during the first four
weeks of treatment, this may represent a sensitive mea-
sure of impending renal failure.
5) Other objective measures that may have predictive
value of acute renal failure should also be sought
Because of the limited value of serum chemistries for
detection of nephropathy, other measures of renal func-
tion should be considered. The collection and analysis
of urine may be of some benefit, but defined criteria for
drug withdrawal are lacking. Urinary glucose, protein,
and specific gravity can be easily and rapidly measured
on samples and will likely reveal abnormalities during
PMPA treatment. Other measures that might prove use-
ful include urinary b2-microglobulin and urinary pro-
tein/creatinine ratio. Point-of-care diagnostic devices are
available to facilitate measurement of the latter and
might be considered. As with serum chemistry evalua-
tions, increased sample frequency during high dose
treatment may be beneficial. While potentially useful,
further work will be required to develop objective cri-
teria for drug withdrawal.
Methods
Nonhuman Primate Studies
The nonhuman primate study was conducted at South-
ern Research Institute in Frederick, MD and was
approved by the Institutional Animal Care and Use Com-
mittee. Briefly, male Indian-origin rhesus macaques were
inoculated intravenously with 1,000 TCID50 SIVmac239
5 10 15
-0.5
0.0
0.5
1.0
r=0.7234;  p=0.0003 A.
Composite histology score
s
l
o
p
e
 
B
U
N
 
v
s
 
t
i
m
e
(
d
a
y
s
/
(
m
g
/
d
l
)
)
5 10 15
-1.0
-0.5
0.0
0.5
1.0
r=0.4631;  p=0.0398
B.
composite histologic score
s
l
o
p
e
 
P
h
o
s
p
h
o
r
u
s
 
v
s
 
t
i
m
e
(
d
a
y
s
/
(
m
g
/
d
l
)
)
Figure 6 Correlation of BUN and phosphorus slope with
composite ART nephropathy score. Correlation of BUN (r =
0.7234; p = 0.0003) and phosphorus (r = 0.4631; p = 0.0398) slope
with composite ART nephropathy score reveals statistical
significance. Black dots represent individual animals.
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Page 9 of 11and followed prospectively with sequential blood draws
used for determination of viral load, CD4 T cell numbers,
complete blood counts, and serum chemistries. Animals
were started on ART 3 months after SIV infection and
treated for 6 months. ART consisted of PMPA (20-30
mg/kg/SC SID), d4T (stavudine; 1.2 mg/kg BID PO) and
FTC (emtricitabine; 50 mg/kg SC SID). PMPA was given
at 30 mg/kg for the first month and then reduced to 20
mg/kg thereafter. During ART, animals received a thera-
peutic SIV DNA vaccine four times in four-week inter-
vals. A subset of animals also received Proleukin
® from
day 2-16 after vaccination, and the animals were followed
for 75 weeks when the study was terminated [12]. Two
animals developed biochemical evidence of acute renal
failure during the treatment period, and others subse-
quently developed morphologic evidence of nephropathy.
The purpose of this analysis was to summarize histologi-
cal findings within renal tissue and examine serum bio-
chemistry correlates of these changes to identify
predictors of disease occurrence useful in the manage-
ment of future studies.
Histopathology
Paraffin-embedded, formalin-fixed renal tissue from 21
animals was available for histopathology. Sections were
cut and routinely stained with hematoxylin and eosin.
Objective criteria were developed to provide a measure
of renal tubular pathology (Table 3) and were applied to
the evaluation of tissues in a blinded fashion. A compo-
site ART nephropathy score was generated through the
addition of individual tubular pathology values. Excellent
agreement was found between this composite score and
a subjective nephropathy score (0, normal; 1 mild; 2,
moderate; and 3, severe) (r = 0.9454; p < 0.0001) gener-
ated in an independent and blinded fashion.
Serum chemistry
Serum chemistry values for BUN, creatinine, phos-
phorus, calcium, albumin, globulin, sodium, chloride,
and alkaline phosphatase were measured using a VetS-
can Chemistry Analyzer (Abaxis, Inc.) every 2 to 4
weeks. At defined time points (base line (t = 0), initia-
tion of ART (t = 92 days), 2 weeks of ART (105 days), 4
weeks of ART (119 days), termination of ART (284
days), and study end (day of death) values were com-
pared to composite and individual pathology scores
using statistical software (GraphPad Prism 4). In addi-
tion, linear regression analysis was performed for data
sets from individual animals to determine, which ani-
mals had statistically significant changes in phosphorus,
BUN, and creatinine over time. The slopes of these
changes were then compared to composite ART
nephropathy scores to determine whether morphologic
changes correlated with biochemical changes.
Acknowledgements
This work was supported by NIH/NIAID contract N01-AI-15451. PMPA and
FTC were kindly provided by Gilead Corporation, and Zerit
® was a gift from
the AIDS Research and Reference Reagent Program, NIAID, NIH. We would
also like to thank Dr. Ron Desrosiers for donating the SIVmac239 challenge
stock, and Audra Hachey for tissue processing.
Author details
1Southern Research Institute, Frederick, MD, USA.
2Harvard Medical School,
New England Primate Research Center, Southborough, MA, USA.
3BIOQUAL,
Inc., 9600 Medical Center Drive, Rockville, MD 20850, USA.
4Vaccine Research
Program, Division of AIDS/NIAID/NIH, 6700B Rockledge Drive, Bethesda, MD
20817, USA.
Authors’ contributions
BES-B and YES designed and supervised the study. DG, AL, DH, and LN-D
were carrying out the technical aspects of the study, such as CBC and serum
chemistries and RNA viral loads. LR performed the veterinary supervision,
clinical observations and therapeutic interventions on the animals. KM
conducted the histopathology evaluations and the correlations with serum
chemistries. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 October 2010 Accepted: 21 January 2011
Published: 21 January 2011
References
1. Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA, Shaw JP:
Pharmacokinetics and bioavailability of the anti-human
immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)
propyl]adenine (PMPA) in dogs. Antimicrob Agents Chemother 1998,
42:687-690.
2. Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A,
Hamilton M, Hirst LL, Bennett DR, Canfield DR, et al: Biological effects of
short-term or prolonged administration of 9-[2-(phosphonomethoxy)
propyl]adenine (tenofovir) to newborn and infant rhesus macaques.
Antimicrob Agents Chemother 2004, 48:1469-1487.
3. Valle R, Haragsim L: Nephrotoxicity as a complication of antiretroviral
therapy. Adv Chronic Kidney Dis 2006, 13:314-319.
4. Alpers CE, Tsai CC, Hudkins KL, Cui Y, Kuller L, Benveniste RE, Ward JM,
Morton WR: Focal segmental glomerulosclerosis in primates infected
with a simian immunodeficiency virus. AIDS Res Hum Retroviruses 1997,
13:413-424.
5. Gattone VH, Tian C, Zhuge W, Sahni M, Narayan O, Stephens EB: SIV-
associated nephropathy in rhesus macaques infected with lymphocyte-
tropic SIVmac239. AIDS Res Hum Retroviruses 1998, 14:1163-1180.
6. Stephens EB, Tian C, Li Z, Narayan O, Gattone VH: Rhesus macaques
infected with macrophage-tropic simian immunodeficiency virus
(SIVmacR71/17E) exhibit extensive focal segmental and global
glomerulosclerosis. J Virol 1998, 72:8820-8832.
7. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N,
Lifson JD, Morton WR: Effectiveness of postinoculation (R)-9-(2-
phosphonylmethoxypropyl) adenine treatment for prevention of
persistent simian immunodeficiency virus SIVmne infection depends
critically on timing of initiation and duration of treatment. J Virol 1998,
72:4265-4273.
8. Tsai CC, Follis KE, Beck TW, Sabo A, Bischofberger N, Dailey PJ: Effects of
(R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV
infection in macaques. AIDS Res Hum Retroviruses 1997, 13:707-712.
9. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N,
Benveniste RE, Black R: Prevention of SIV infection in macaques by (R)-9-
(2-phosphonylmethoxypropyl)adenine. Science 1995, 270:1197-1199.
10. Van Rompay KK, Marthas ML, Lifson JD, Berardi CJ, Vasquez GM, Agatep E,
Dehqanzada ZA, Cundy KC, Bischofberger N, Pedersen NC: Administration
of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of
perinatal simian immunodeficiency virus infection in rhesus macaques.
AIDS Res Hum Retroviruses 1998, 14:761-773.
11. Van Rompay KK, Miller MD, Marthas ML, Margot NA, Dailey PJ, Canfield DR,
Tarara RP, Cherrington JM, Aguirre NL, Bischofberger N, Pedersen NC:
Sanders-Beer et al. AIDS Research and Therapy 2011, 8:3
http://www.aidsrestherapy.com/content/8/1/3
Page 10 of 11Prophylactic and therapeutic benefits of short-term 9-[2-(R)-
(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn
macaques following oral inoculation with simian immunodeficiency
virus with reduced susceptibility to PMPA. J Virol 2000, 74:1767-1774.
12. Zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A,
Hebblewaite D, Sites D, Nieves-Duran L, Srivastava R, Otten GR, et al: A
therapeutic SIV DNA vaccine elicits T-cell immune responses, but no
sustained control of viremia in SIVmac239-infected rhesus macaques.
AIDS Res Hum Retroviruses 2008, 24:1103-1116.
13. Durand-Gasselin L, Van Rompay KK, Vela JE, Henne IN, Lee WA, Rhodes GR,
Ray AS: Nucleotide analogue prodrug tenofovir disoproxil enhances
lymphoid cell loading following oral administration in monkeys. Mol
Pharm 2009, 6:1145-1151.
14. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T,
Spinner A, Jerome C, Moore J, Kearney BP, et al: Chronic administration of
tenofovir to rhesus macaques from infancy through adulthood and
pregnancy: summary of pharmacokinetics and biological and virological
effects. Antimicrob Agents Chemother 2008, 52:3144-3160.
15. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S,
Luo W, Kim C, Adams DR, Monsour M, et al: Prevention of rectal SHIV
transmission in macaques by daily or intermittent prophylaxis with
emtricitabine and tenofovir. PLoS Med 2008, 5:e28.
16. Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to
human studies revisited. Faseb J 2008, 22:659-661.
17. Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N:
Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA)
to gravid and infant rhesus macaques (Macaca mulatta): safety and
efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999,
20:323-333.
18. Crowther MA, Callaghan W, Hodsman AB, Mackie ID: Dideoxyinosine-
associated nephrotoxicity. AIDS 1993, 7:131-132.
19. Morris AA, Baudouin SV, Snow MH: Renal tubular acidosis and
hypophosphataemia after treatment with nucleoside reverse
transcriptase inhibitors. AIDS 2001, 15:140-141.
20. Krishnan M, Nair R, Haas M, Atta MG: Acute renal failure in an HIV-positive
50-year-old man. Am J Kidney Dis 2000, 36:1075-1078.
21. Izzedine H, Launay-Vacher V, Deray G: Fanconi syndrome associated with
didanosine therapy. AIDS 2005, 19:844-845.
doi:10.1186/1742-6405-8-3
Cite this article as: Sanders-Beer et al.: Clinical monitoring and correlates
of nephropathy in SIV-infected macaques during high-dose
antiretroviral therapy. AIDS Research and Therapy 2011 8:3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sanders-Beer et al. AIDS Research and Therapy 2011, 8:3
http://www.aidsrestherapy.com/content/8/1/3
Page 11 of 11